KMB Bears Sit on 16% Float as Kenvue Deal Looms Over October Print

Kimberly-Clark heads into its October 20 results carrying one of the heavier short positions in the household-products sector, alongside an unresolved deal story that is reshaping the company's share count and index weights at the same time.

Short sellers have built a substantial position. At 15.5% of the free float, short interest has climbed 16% over the past month and now ranks in the bottom 5th percentile of the universe on the ORTEX short score rank, with the ORTEX short score itself a firmly bearish 75. The borrow market, however, offers no squeeze catalyst. Availability is comfortable at 234%, meaning roughly 2.3 shares remain available to borrow for every share already shorted. Borrowing costs are a negligible 0.54%, barely moved on the week. Options positioning adds a mildly constructive counter-signal: the put/call ratio of 0.67 is running about 1.4 standard deviations below its 20-day average, pointing to less hedging demand than usual, even as the stock has gained 8% over the past week and nearly 7% over the past month to close at $105.57.

The analyst community is divided and in motion. Bears point to a specific and well-documented set of pressures for the quarter: estimates have been cut by roughly two percentage points to account for a postponed innovation launch and inventory de-loading, a 250 basis-point China drag, $30 to 40 million of extra freight costs, and about $40 to 50 million of incremental input cost pressure. The company's own guidance implies an approximately 70 basis-point EBIT margin headwind, with organic revenue growth guided negative at roughly minus 1.3% for the quarter and EPS revised down to $7.30 for the full year. On the other side, bulls point to the durability of Huggies, Kleenex and Kotex in essential categories, geographic diversification across North America and Europe, and a five-year $3 billion productivity programme that should restore margin momentum over a multi-year horizon. BNP Paribas moved its target to $110 from $101 on the eve of the print, though TD Cowen and Wells Fargo both trimmed targets in the days prior. The consensus mean sits at $114.80, implying about 9% upside from current levels.

The larger context is the pending Kenvue acquisition, which introduces a structural complication for this print and several that follow it. ORTEX forecasts an 80% probability of a share-count increase in the S&P 500 and an 84% chance across the Russell 1000 and Russell 3000 following the deal close, with estimated S&P 500 trade-date around late November (dates are estimated). The addition of Kenvue's consumer health portfolio is central to the bull case on synergies and growth profile. It is also why index tracker flows, rather than near-term organic revenue, may drive more of the stock's price action over the coming months than any single earnings release.

The October 20 print will test whether management can hold margin guidance credibly in the face of the freight and input cost pressures bears have already priced in, or whether the innovation delays and China weakness represent a deeper reset in the company's near-term growth trajectory.